Administration of alkylating agents (Alk), topoisomerase II inhibitors (Topo II) and radiotherapy (RT) can result in therapy-related myelodysplastic syndrome or acute myelogenous leukaemia (t-MDS/t-AML), the optimal treatment for which is allo-SCT. A retrospective review was performed of 24 patients who underwent related-or unrelated-donor SCT for t-MDS/t-AML at our institution. Eight patients remain alive and in continuous remission (median follow-up 54 months (range, 12-161)) with estimated 5-year EFS being 30% (95% confidence intervals 16-58%). Corresponding actuarial risks of relapse and non-relapse mortality (NRM) are 39% (19-60%) and 30% (13-50%), respectively. EFS was 40% in Alk/RT-related t-MDS/t-AML and 11% in Topo II-related t-MDS/t-AML (P ¼ 0.05), with an increased risk of relapse in the latter (56 vs 29%, respectively (P ¼ 0.05)). In multivariate analysis, development of acute GVHD (P ¼ 0.009) and Topo II-related t-MDS/t-AML (P ¼ 0.018) were associated with inferior EFS. Patients with acute GVHD had an increased risk of NRM (P ¼ 0.03) whereas risk of relapse was higher for patients of advanced age (P ¼ 0.046) and for patients who underwent bone marrow (vs blood) SCT (P ¼ 0.032). Allo-SCT can result in long-term survival for individuals with t-MDS/t-AML although outcome in Topo II-related t-MDS/t-AML patients remains suboptimal.
Introduction
Patients who have previously received chemotherapy and/ or radiation treatment are predisposed to develop therapyrelated myelodysplastic syndrome or AML (t-MDS/ t-AML). [1] [2] [3] The incidence of these disorders is rising because of improved primary malignancy outcomes, most notably in childhood ALL and non-Hodgkin's lymphoma. 4 In contrast to de novo MDS, BM cytogenetic abnormalities are demonstrable in over 90% of cases of t-MDS/t-AML. 1, 2 Moreover, it has now been recognized that there are two broad categories of t-MDS/t-AML, one that occurs after exposure to alkylating agents (Alk) or radiation (RT) and is typically associated with abnormalities of chromosomes 5 and/or 7, and a second disorder, following treatment with topoisomerase II inhibitors (Topo II), which is associated with a shorter latency period, balanced chromosomal translocations and a more favourable initial response to chemotherapy. [5] [6] [7] CR is achieved in a minority of patients with t-MDS/t-AML after conventional chemotherapy is given and, even when documented, is typically brief. 8 As a result, long-term survival is unlikely without the use of high-dose therapy and SCT. Auto-SCT has been used in selected patients with t-MDS/t-AML who enter CR with conventional chemotherapy with modest success. 9, 10 However, allo-SCT is generally recommended for these individuals, provided a suitably matched related or unrelated donor can be identified. Initial results of allo-SCT in this patient cohort, including our own institution's experience, were disappointing and suggested that outcomes were inferior to that observed in de novo (primary) MDS/sAML. [11] [12] [13] It is noteworthy that these early SCT reports frequently grouped t-MDS/t-AML patients with those that had AML evolving from primary MDS ('secondary AML' or sAML), making interpretation of outcomes more difficult. To accurately determine the success rate with allo-SCT for t-MDS/t-AML and to better define risk factors for outcome in this population, a review was performed of patients who underwent related-and unrelated-donor SCT for this diagnosis over an 18-year period at our institution.
Patients and methods

Patient characteristics
A retrospective computerized data base review was performed to identify patients referred to the Leukaemia/ Bone Marrow Transplantation Program of British Columbia with a diagnosis of t-MDS/t-AML. Between March 1989 and January 2007, 122 patients with t-MDS/t-AML were evaluated at Vancouver General Hospital. The majority (74 patients, 61%) were not considered as candidates for SCT based upon advanced age or medical comorbidities. Six patients with good-risk karyotypes received standard chemotherapy only, six patients underwent auto-SCT and one patient had a reduced-intensity conditioning allo-SCT. Eight patients died of disease progression before a donor could be identified and three patients left the province to receive treatment. Twenty-four patients (20%) actually proceeded to myeloablative allo-SCT, with the characteristics of this cohort shown in Table 1 . Some of the patients in the cohort have previously been reported in meeting abstracts or published manuscripts. 10, 11, 14 All subjects provided informed consent and all research studies were approved by the University and Institutional Review Boards. Bone marrow histopathology was centrally reviewed at Vancouver General Hospital and diagnoses were based upon published WHO criteria. 6 Seven patients had t-MDS and IPSS scores were intermediate-2 in five patients, intermediate-1 in one patient and high-risk in one patient. The remaining 17 patients had t-AML. Of the 21 patients who had received prior chemotherapy, three had received an Alk without any history of exposure to Topo II and two had received an epipodophyllotoxin without any history of exposure to an Alk or radiotherapy; one patient had been given only azathioprine for Crohn's disease. The remaining 15 patients had received both an Alk and a Topo II inhibitor. As a result, Topo-II-related t-MDS/t-AML was diagnosed based on specific established clinical, morphologic and cytogenetic criteria. 5 All nine of the patients with Topo II-related tAML had at least two of the following: lack of a preceding MDS phase (eight patients), typical karyotypic changes (t(9;11) in four cases; t(8;16) or t(8;21) in one case each), monoblastic morphology (six patients), a short latency period (less than 3 years) and/or a history of having been treated on dose-intensive epipodophyllotoxin-containing Pediatric Oncology Group protocols. 15 As per institutional policy, conventional cytoreductive chemotherapy (high-dose cytosine arabinoside and daunorubicin or mitoxantrone/etoposide) was administered only when required for hematologic stabilization to allow for tissue typing of potential donors. 16 Of the 11 patients who required conventional chemotherapy, all achieved an initial CR. However, three patients had evidence of recurrent t-MDS/t-AML on bone marrow exams performed just before starting the SCT preparative regimen. Thirteen patients did not require standard AML induction chemotherapy before commencing transplantation conditioning although, two patients had previously received immunosuppressive treatment with anti-thymocyte globulin and CYA without benefit. Four patients in the study group previously underwent auto-SCT for a separate primary malignancy.
Cytogenetics
Cytogenetic analyses were performed on direct and/or unstimulated cultured marrow specimens at four reference laboratories and reviewed at Vancouver General Hospital. All 24 patients in this report had successful bone marrow karyotyping before SCT. Patients were divided into prognostic cytogenetic subgroups according to accepted MRC criteria for AML. 7 In brief, favourable karyotypes were those patients with t(15;17), t(8;21), or inv(16)/ t(16;16), whether or not other abnormalities were also present. Adverse karyotypes were those with monosomy 5 or 7, del(5q), abnormalities of 3q or a complex karyotype (Xfive abnormalities), in the absence of the aforementioned favourable translocations. All patients who did not have favourable or adverse karyotypes were classified as intermediate-risk. All seven patients with therapy-induced MDS were categorized in the identical cytogenetic subgroup that each would have been, had the IPSS cytogenetic grouping 17 been used (six patients poor-risk and one patient intermediate-risk). 
SCT
Transplantation details are shown in Table 2 . Twenty-one patients underwent SCT from a 'matched' donor. Donor and recipient histocompatibility testing was performed serologically for the first four patients (one unrelated recipient was A-antigen mismatched) and by high-resolution 10-loci DNA-based class I and II techniques for the final 11 patients (one unrelated recipient was A-antigen mismatched and one unrelated recipient was C-antigen mismatched). The remaining nine donor/recipient pairs had class I serological and class II DNA-based testing performed (one related recipient was A-antigen mismatched). All conditioning regimens contained conventional (myeloablative) doses. Patients conditioned with high-dose BU were given phenytoin as seizure prophylaxis 18 and all patients received uroepithelial prophylaxis with hyperhydration (3 l/m 2 /day). Supportive care was previously described in detail. 16, 19, 20 In brief, all patients were treated in rooms equipped with high-efficiency particulate air filtration. The final 20 patients in the study routinely received hepatic veno-occlusive disease prophylaxis with low-dose IV heparin 21 and antifungal prophylaxis with either IV fluconazole or low-dose amphotericin B. Treatment of established acute GVHD was with highdose methylprednisolone; those resistant to methylprednisolone received rabbit anti-thymocyte globulin (Thymoglobulin, Genzyme Corp, Cambridge, MA, USA).
Statistical methods
Survival and actuarial risk of acute and chronic GVHD was determined by the Kaplan-Meier method. 22 Risk of relapse and non-relapse mortality (NRM) was calculated using a competing risks technique. 23 Factors analyzed with respect to survival, relapse and NRM included: age at SCT and disease duration (both as continuous variables), gender, disease (t-MDS vs t-AML), MRC cytogenetic classification (favourable/intermediate vs adverse), disease status (untreated vs CR1 vs other), predisposing chemoradiotherapy treatment (Alk/RT-vs Topo II-related), prior auto-SCT, stem cell source (blood vs marrow), donor type (related vs unrelated) and conditioning regimen (BU-vs TBI-based). Univariate and multivariate analyses of prognostic factors were performed using a proportional hazards Cox regression model. 24 
Results
Survival
Eight of 24 patients remain alive and in continuous CR (AML seven patients, refractory anaemia one patient), with a median follow-up of 54 months (range, 12-161 months). The estimated 5-year EFS for the entire group (Figure 1 ) is 30% (95% confidence intervals (CI) 16-58%). Patients with Alk/RT-related t-MDS/t-AML had a 5-year EFS of 40% (CI 35-65%) whereas patients with a Topo II-related t-MDS/t-AML had an EFS of only 11% (Figure 1 ; P ¼ 0.05).
Performance status
At last follow-up, Karnofsky performance status was X90% in seven of eight surviving patients. One patient, a 50-year-old man who previously underwent auto-SCT for AML, had a KPS of 80% secondary to bronchiolitis obliterans following unrelated donor SCT. Three other patients remain on low-dose immunosuppression for chronic GVHD. One patient (a 27-year-old female) developed a squamous cell carcinoma of the tongue 11 years post-unrelated donor SCT for Topo II-related AML with þ 8. She was treated with surgery and local radiotherapy and, 30 months later, remains the only Topo II-related AML survivor. A second patient (a 60-year-old female) had a myocardial infarction 4.5 years postunrelated donor SCT that was treated with coronary artery angioplasty and stent insertion. A third patient is on thyroid replacement after having been found to have occult primary hypothyroidism 6 years post-unrelated donor SCT.
Non-relapse mortality The cumulative incidence of acute and chronic GVHD for all patients was 43% (CI 19-60%) and 88% (CI 35-98%), respectively. Seven patients died of NRM, including four patients from GVHD, two of whom had received prior auto-SCT. Two patients died of regimen-related toxicity (cardiac and neurologic in one patient each) and one patient died of infection (pulmonary Aspergillosis). The actuarial risk of NRM for the entire cohort was 30% (CI 13-50%).
Relapse
Nine patients experienced a relapse of t-MDS/t-AML following allo-SCT, all but one within 10 months of SCT (median 4 months). One of these patients previously underwent auto-SCT for lymphoma. Actuarial risk of relapse ( Figure 2 ) was 39% (CI 20-50%). Five of the nine relapses were in patients with a Topo II-related AML, with four of these relapses occurring between two and five months post-SCT. The fifth patient with Topo II-related t-MDS/t-AML had a relapse 55 months following matched sibling SCT. Relapse was more common following SCT for Topo II-related (5-year actuarial risk 56%) vs Alk/RTrelated (actuarial risk 29%, P ¼ 0.05) t-MDS/t-AML ( Figure 2 ). For each patient that relapsed, survival was short, with none of the nine patients surviving more than 2 months from documentation of recurrence.
Univariate analysis of risk factors
Results of the univariate analyses for EFS, relapse and NRM are shown in Table 3 . WHO diagnosis (Alk/RTrelated vs Topo II-related t-MDS/t-AML, P ¼ 0.05) and the development of Xgrade II acute GVHD (P ¼ 0.003) were the only significant variables with regard to EFS and the development of Xgrade II acute GVHD was the only factor significantly correlated with NRM (P ¼ 0.01). WHO diagnosis (P ¼ 0.05), interval from diagnosis to SCT (P ¼ 0.03) and the absence of chronic GVHD (P ¼ 0.05) were all found to be predictive of relapse.
Multivariate analysis of risk factors
Results of the multivariate analyses of variables predictive for EFS, relapse and NRM are shown in Table 4 . The development of Xgrade II acute GVHD (P ¼ 0.009) and AML WHO subtype (Alk/RT-related vs Topo II-related t-MDS/t-AML; P ¼ 0.018) were both predictive of EFS. Grade XII acute GVHD (P ¼ 0.03) was the only significant variable predictive of NRM in multivariate analysis. Younger age at SCT and blood as a stem cell source were both associated with a lower risk of relapse and the presence of chronic GVHD was of borderline significance (P ¼ 0.07). Cytogenetic risk group was not a risk factor for either EFS or relapse.
Discussion
There remains significant controversy regarding the success of allo-SCT for t-MDS/t-AML. Initial reports had suggested an inferior outcome when compared with results seen in primary MDS, with long-term EFS of 0-27%. [11] [12] [13] 25, 26 Although the current study involves a relatively small group of patients receiving heterogenous treatments over an 18-year period, the overall findings are more consistent with recent reports that support equivalent outcomes for the two patient populations.
27-29
The reasons for the initial reports of inferior outcomes in t-MDS/t-AML when compared with primary MDS are likely complex. Our published SCT results for primary MDS show an EFS of 29%, with a significant risk of both relapse and non-relapse mortality. 16 The original negative report from our centre regarding SCT for t-MDS/t-AML (only 1 of 20 patients survived) did not distinguish between t-MDS/t-AML and sAML.
11 Furthermore, 9 of 12 patients treated with conventional induction chemotherapy had active t-MDS/t-AML at SCT and five of eight patients with t-MDS/t-AML had Topo II-related disease. Although 12 of 20 patients in this initial cohort died of treatment-related toxicities, this might have been reduced by better patient/ donor selection, recent improvements in supportive care and increasing SCT expertise with this unique group of patients.
SCT outcome in primary MDS at our institution has been closely correlated with poor-risk cytogenetics, which is associated with a high relapse rate and an inferior survival. 16 Bone marrow karytope was not found to be predictive of either relapse or survival following SCT in our t-MDS/t-AML patients. However, the development of chronic GVHD appears to be important in reducing relapse rates post-SCT in both primary MDS and in t-MDS/ t-AML. The largest single institution SCT study exclusively containing patients with t-MDS/t-AML was published by the Seattle group. 30 They reported a 5-year EFS of only 16% in a cohort of 111 patients, with NRM being particularly high (53%). However, the investigators did note that targeted BU/CY conditioning (tBuCy) led to a more favourable 5-year EFS of 30%, primarily because of less regimen-related toxicity. Few patients in this study received conventional cytoreduction before conditioning and the risk of relapse directly correlated with marrow blast percentage. Chang et al 28 recently updated the Seattle The largest registry studies of SCT for t-MDS/t-AML are from the Societe´Franc¸ais de Greffe de Moelle and from the EBMT. 27, 29 The former noted a 2-year EFS of 28% and the latter a 3-year EFS of 31%. Contrary to the reports from Seattle, a large proportion of patients in both studies had received conventional cytoreductive chemotherapy before conditioning. Not surprisingly, patients in CR at the time of SCT had a lower risk of relapse in both European studies. A key predictor of EFS in a multivariate analysis in the French and EBMT reports, as in the Seattle experience, was younger age. The EBMT also identified marrow blast count and abnormal cytogenetics as predictors of EFS. Although age did influence the outcome in our institutional experience with SCT in t-MDS/t-AML, perhaps reflecting a more aggressive disease biology in older patients, we found no effect of marrow blast cell percentage or cytogenetic risk group on relapse or EFS.
The current report from our centre has identified Topo II-related t-MDS/t-AML as a subgroup of patients with an unfavourable outcome (5-year EFS 11 vs 50% for Alk/ RT-related t-MDS/t-AML), with post-SCT relapse being particularly problematic. This disorder was first described by Pui et al 31 . in pediatric ALL patients exposed to doseintensive epipodophyllotoxins. In a follow-up report from the same centre, a long-term EFS of only 10% was reported for 35 such patients, 70% of whom had an 11q23 chromosomal abnormality. 4 A number of subsequent studies [32] [33] [34] were consistent in concluding that allo-SCT in children with epipodophyllotoxin-related t-MDS/t-AML was associated with a poor EFS. However, there have been no previous reports specifically describing long-term EFS for adults with Topo II-related t-MDS/t-AML.
A previous study from our centre did report on SCT results for patients with both de novo and therapy-related acute leukaemia and 11q23 abnormalities. 10 Three of 9 patients with de novo AML in this analysis remain alive and free of leukaemia, including one patient who underwent sibling SCT with a high-dose Bu regimen, one patient who was conditioned with a TBI regimen prior to unrelated donor SCT and one patient who received high-dose Bu and a purged autograft. This experience would suggest that an 11q23 abnormality, in its own right, does not predict for a poor prognosis following SCT. It is interesting to note that one patient in this study had a successful Bu-based autograft for tAML with t(9;11). None of the five patients in our current study with Topo II-related t-MDS/t-AML who received Bu-based conditioning were long-term survivors.
Following the original reports of epipodophyllotoxinrelated t-MDS/t-AML, it has now been recognized that other Topo II inhibitors, especially anthracyclines, can also cause t-MDS/t-AML. 5 As a result, the WHO Classification now recognizes Topo II-related t-MDS/t-AML as a distinct entity. 6 Furthermore, when this condition occurs in adults, it may also present with chromosomal changes that are typically associated with a favourable outcome in de novo AML (t(8;21), t(15;17) and inv (16) ). It remains uncertain whether these chromosomal changes result in equivalent outcomes for t-AML as in de novo AML. 2, 7, 35 Despite recent improvements in SCT outcome for t-MDS/t-AML, the results in Topo II-related t-MDS/ t-AML remain suboptimal. The use of less toxic conditioning regimens, such as tBuCy or RICT could further improve survival. The EFS reported by King's College Hospital 36 and the City of Hope 37 using an RICT approach for MDS are impressive. An alternative approach might be the routine use of conventional chemotherapy to induce a CR before commencing SCT conditioning. This remains controversial with proponents suggesting it reduces risk of post-SCT relapse, 27 and opponents finding it is associated with undue toxicity without a measurable improvement in EFS. 38 Finally, there is ample evidence to support that the routine use of blood stem cells rather than bone marrow leads to a superior EFS in high-risk patients undergoing SCT. 39, 40 It is less clear whether this is strictly because of a reduction in NRM or, as in our current analysis, also related to a lower risk of relapse.
Allo-SCT can result in long-term EFS for patients with t-MDS/t-AML although it is noteworthy that the vast majority of patients seen at our centre during the time period of the study were not able to proceed to SCT. Furthermore, in those individuals who were able to undergo SCT, outcomes were less favourable if the t-MDS/t-AML was related to prior exposure to Topo II inhibitors. Future treatment strategies in this patient population will need to focus on increasing the number of patients eligible to proceed to allo-SCT and on reducing both NRM and relapse rates following the procedure.
